Plants-derived neuroprotective agents: cutting the cycle of cell death through multiple mechanisms
Open accessAbstract
Neuroprotection is the preservation of the structure and function of neurons from insults arising from cellular injuries induced by a variety of agents or neurodegenerative diseases (NDs). The various NDs including Alzheimer's, Parkinson's, and Huntington's diseases as well as amyotropic lateral sclerosis affect millions of people around the world with the main risk factor being advancing age. Each of these diseases affects specific neurons and/or regions in the brain and involves characteristic pathological and molecular features. Hence, several in vitro and in vivo study models specific to each disease have been employed to study NDs with the aim of understanding their underlying mechanisms and identifying new therapeutic strategies. Of the most prevalent drug development efforts employed in the past few decades, mechanisms implicated in the accumulation of protein-based deposits, oxidative stress, neuroinflammation, and certain neurotransmitter deficits such as acetylcholine and dopamine have been scrutinized in great detail. In this review, we presented classical examples of plant-derived neuroprotective agents by highlighting their structural class and specific mechanisms of action. Many of these natural products that have shown therapeutic efficacies appear to be working through the above-mentioned key multiple mechanisms of action.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
WS extracts increase autophagy in OD1 G93A mice.
“| WS extracts | frontotemporal lobar degeneration (FTLD) ALS | OD1 G93A mice | Increase in immunomodulatory effect, autophagy, | [97,98] |”
From Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects (2021) · cites this paper as [97]
WS extracts increase immunomodulatory effect in OD1 G93A mice.
“| WS extracts | frontotemporal lobar degeneration (FTLD) ALS | OD1 G93A mice | Increase in immunomodulatory effect, autophagy, | [97,98] |”
From Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects (2021) · cites this paper as [97]
WS extracts reduce ALS in OD1 G93A mice.
“| WS extracts | frontotemporal lobar degeneration (FTLD) ALS | OD1 G93A mice | Increase in immunomodulatory effect, autophagy, | [97,98] |”
From Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects (2021) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 318 · Cited by 107
Research works printed but not linked: 1
- [263]Roselli M. Cavalluzzi M. M. Bruno C. Synthesis and evaluation of berberine derivatives and analogues as potential anti-acetylcholinesterase and antioxidant agents Phytochemistry Letters 2016 18 150 156 10.1016/j.phytol.2016.10.005 · DOI
- Authors
- Elufioye, T. O., Berida, T. I., & Habtemariam, S.
- Affiliations
- University of Ibadan (NG)
- University of Greenwich (GB)
- Corresponding author
- Habtemariam, Solomon
- Venue
- Evidence-based Complementary and Alternative Medicine
- Publisher
- Wiley
- Published
- 2017-01
- Volume
- 2017
- Issue
- 1
- Pages
- 3574012-3574012
- ISSN
- 1741-427X (ISSN-L)
- 1741-4288
- PMC
- PMC5585568
- OpenAlex
- W2748130517
- Cited by
- 107
- References
- 318
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 18 · 2023: 12 · 2022: 12 · 2021: 16 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 1
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Evidence-based Complementary and Alternative Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Greenwich Academic Literature Archive (University of Greenwich) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, neuroinflammation, oxidative stress, acetylcholine deficiency, dopamine deficiency, protein deposits, natural products, mechanism of action
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review